Pharmacokinetics, Disposition, and Biotransformation of [14C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion
Elijah Weber(Gilead Sciences (United States)), Renu Singh(Gilead Sciences (United States)), Jennifer E. Sager(VIR Biotechnology (United States)), Michael Graupe(Gilead Sciences (United States)), Scott A. Wolckenhauer(Gilead Sciences (United States)), Ramesh Palaparthy(Gilead Sciences (United States)), William Rowe(Gilead Sciences (United States)), Gong Shen(Gilead Sciences (United States)), John Ling(Gilead Sciences (United States)), Raju Subramanian(Gilead Sciences (United States)), Martin S. Rhee(Gilead Sciences (United States)), Rebecca Begley
Cited by 17
Related Papers
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
|Drug Metabolism and Disposition|2002|346
Effects of Fibrates on Metabolism of Statins in Human Hepatocytes
|Drug Metabolism and Disposition|2002|325
Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection
|New England Journal of Medicine|2022|312
Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons
|New England Journal of Medicine|2024|260